Kavanagh, J. J., Levenback, C. F., Ramirez, P. T., Wolf, J. L., Moore, C. L., Jones, M. R., . . . Bast, R. C. (2010). Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. BioMed Central.
Citação norma ChicagoKavanagh, John J., Charles F. Levenback, Pedro T. Ramirez, Judith L. Wolf, Carla L. Moore, Marsha R. Jones, Lisa Meng, Gail L. Brown, and Robert C. Bast. Phase 2 Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin in Platinum and Paclitaxel Refractory or Resistant Epithelial Ovarian Cancer. BioMed Central, 2010.
Citação norma MLAKavanagh, John J., et al. Phase 2 Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin in Platinum and Paclitaxel Refractory or Resistant Epithelial Ovarian Cancer. BioMed Central, 2010.